Compare Freeport-McMoRan Inc (FCX) vs Novartis AG (NVS) Price & Performance

Freeport-McMoRan IncTrade

Novartis AGTrade

Price performance (Past 24H)

Key statistics

Freeport-McMoRan Inc vs Novartis AG — how do they compare? Freeport-McMoRan Inc trades at $69.21 (market cap $98.71B), while Novartis AG trades at $153.53 (market cap $298.18B). The key difference: Novartis AG is far larger — about 3× Freeport-McMoRan Inc's market cap, and Novartis AG pays the higher dividend (3.02%). Which is the better fit depends on your goals.

	FCX	NVS
Market Cap	$98.71B	$298.18B
Sector	Basic Materials	Health
52-Week High	$71.73	$168.62
52-Week Low	$35.34	$119.31
Enterprise Value	$104.99B	$339.50B
Dividend Yield	0.85%	3.02%

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

FCX

Freeport-McMoRan poised for growth with strong copper market and solid financials, supporting a Buy rating.Seeking Alpha · 22 hours agoBullish Freeport's Q2 beats expectations with higher copper output and lower costs, but risks remain.Seeking Alpha · 22 hours agoBullish View details →

NVS

BioCryst hits profitability with strong Q2 revenue, sparking takeover interest in rare disease biotech.24/7 Wall Street · 1 day agoBullish New report analyzes 1,350+ precision medicine deals from 2019-2026, revealing market trends and deal structures.Researchandmarkets.Com · 4 days agoNeutral View details →

About Freeport-McMoRan Inc

Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.